CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial

被引：0
|
作者：
Bennouna, J.
Faroux, R.
Francois, E.
Ligeza, C.
El Hannani, C.
Perrier, H.
Jacob, J.
Desseigne, F.
Perrocheau, G.
Douillard, J. Y.
机构：
[1] Ctr Rene Gauducheau, St Herblain, France
[2] Ctr Hosp La Roche Sur Yon, La Roche Sur Yon, France
[3] Ctr Antoine Lacassagne, Nice, France
[4] Ctr Etienne Dolet, St Nazaire, France
[5] Ctr Hosp Chateaubriand, Chateaubriand, France
[6] Hop St Joseph, Marseille, France
[7] Ctr Francois Baclesse, Caen, France
[8] Ctr Leon Berard, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    Van Cutsem, E.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Nippgen, J.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Results of a phase II trial of cetuximab plus XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer
    Cartwright, T. H.
    Kuefler, P.
    Cohn, A.
    Hyman, W.
    Yoffe, M.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+pts) as first-line treatment in metastatic breast cancer
    Peacock, N. W.
    Spigel, D. R.
    Mainwaring, M. G.
    Thompson, D. S.
    Simons, L.
    Rubin, M. S.
    McCleod, M.
    Harwin, W. N.
    Schreiber, F. J.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Phase II clinical trial with the combination of oxaliplatin-UFT-I,-leucovorin (OXA-UFT-I,LV) for the first line treatment of advanced colorectal cancer (ACC).: Preliminary results (Oncopaz Cooperative Group Spain).
    Dorta, FJ
    Feliú, J
    Vicent, J
    García-Girón, C
    Constenla, M
    Fonseca, E
    Montalar, J
    Lomas, M
    Aparicio, LA
    González-Barón, M
    ANNALS OF ONCOLOGY, 2000, 11 : 50 - 51
  • [45] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Juan José Reina
    Jorge Aparicio
    Javier Salvador
    José María Puerto Pica
    Antonio Rueda
    Antonio Lorenzo
    Carlos González de la Puente
    Pablo Borrega
    José Andrés Moreno-Nogueira
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 339 - 345
  • [46] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
  • [47] 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) plua bevacizumab in patients with metastatic colorectal cancer: Preliminary results of a multicenter phase II trial
    Cordio, S.
    Condorelli, S.
    Rosati, G.
    Soto-Parra, H.
    Caputo, G.
    Rampello, E.
    Salice, P.
    Rimassa, L.
    Pumo, V
    Manzione, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 99 - 99
  • [48] LONG TERM RESULTS OF A MULTICENTRE PHASE II TRIAL ASSESSING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS ACCORDING TO KRAS STATUS
    Samalin, E.
    Francoise, D.
    Thezenas, S.
    Bibeau, F.
    Viret, F.
    Mineur, L.
    Assenat, E.
    Bleuse, J.
    Portales, F.
    Crapez, E.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 23 - 23
  • [49] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
  • [50] Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.
    Bazarbashi, S.
    Aljubran, A. H.
    Soudy, H.
    Darwish, A.
    Eltigani, A.
    Nabil-Ahmed, M.
    Edesa, W.
    Almubarak, M.
    Abu Sabaa, A.
    Shoukri, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345